Clinical Trial Update: Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The Knee [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating CYT-108, a recombinant protease inhibitor, for mild-to-moderate primary osteoarthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Osteoarthritis of the Knee

Drugs mentioned

• CYT-108

Snippet

Sponsor: Cytonics Corporation | Conditions: Osteoarthritis, Knee, Osteoarthritis | Phase 1 | Status: COMPLETED